Value Chain Analysis of the Pharmaceuticals in Brazil.¶

Commercial Relationships¶

The pharmaceutical value chain in Brazil is characterized by a series of intricate commercial relationships spanning from the initial supply of raw materials to the final dispensation of medicines to patients and healthcare institutions. These relationships are heavily influenced by market dynamics, regulatory frameworks, and the diverse nature of the players involved.

At the foundational level, the Input Production (Farmoquímica) stage involves specialized chemical and farmoquímica industries, both national and international, producing Active Pharmaceutical Ingredients (IFAs) and excipients. The commercial relationship here is primarily a Business-to-Business (B2B) transaction where these manufacturers sell raw materials directly to pharmaceutical production companies. Given that Brazil imports approximately 90% of its IFAs, a significant portion of these relationships are with international suppliers, involving complex import processes, customs regulations, and currency exchange considerations. Domestic farmoquímica companies engage in similar B2B sales to national pharmaceutical manufacturers. These relationships are typically governed by supply contracts detailing quality specifications, volumes, pricing, and delivery schedules, which are critical due to the stringent quality requirements for pharmaceutical inputs.

Moving to the Pharmaceutical Production stage, companies (multinational, national, biotech, public laboratories, CMOs) engage in several types of commercial relationships. The primary relationship is the sale of finished pharmaceutical products to distributors, hospitals, clinics, public health entities (SUS), and in some cases, large pharmacy chains directly. This constitutes a major B2B outflow for manufacturers. Multinational companies often operate through local subsidiaries in Brazil, managing sales, marketing, and distribution relationships. National companies compete directly with these multinationals, particularly in the generics and similar medicines segments, focusing on volume and price competitiveness. Public laboratories like Fiocruz and Butantan have unique relationships, often acting as manufacturers and suppliers directly to the public health system (SUS) through specific government procurement processes. Contract Manufacturing Organizations (CMOs) have a B2B relationship with other pharmaceutical companies, offering manufacturing services under contract, producing medicines for their clients. Within this stage, pharmaceutical companies also engage in relationships for Research and Development (R&D). This can involve B2B collaborations with contract research organizations (CROs) for clinical trials, partnerships with research institutions and universities for drug discovery, or licensing agreements with other pharmaceutical companies for technology transfer or commercialization rights. Investment in R&D by the pharmaceutical industry in Brazil is significant, positioning it as one of the sectors with the highest R&D investment, though challenges remain in converting this into domestic API production.

The Distribution stage acts as a crucial intermediary. Wholesale distributors, specialized distributors (e.g., hospitalar), and logistics operators purchase finished products in bulk from pharmaceutical manufacturers (B2B). They then sell and deliver these products to pharmacies, hospitals, clinics, and sometimes government entities (B2B). Distributors are vital for reaching the numerous points of sale and healthcare facilities across Brazil's vast geography. Their commercial model is based on efficient logistics, warehousing under controlled conditions (adhering to regulations like RDC 430/2020), inventory management, and timely delivery. They earn revenue through margins on the products they distribute. The relationships between manufacturers and distributors are characterized by bulk purchasing agreements, credit terms, and logistical coordination. Distributors handle a significant portion of the volume and value of medicines commercialized by retail.

Finally, the Retail and Commercialization stage represents the point of sale to the end consumer or patient. This involves pharmacy chains (large, associative, independent), hospital pharmacies, and public health posts. Their primary commercial relationship is Business-to-Consumer (B2C), selling medicines (prescription and over-the-counter), health, hygiene, and beauty products directly to individuals. Within this stage, there's also a B2B relationship where retailers purchase products from distributors or, less frequently for smaller players, directly from manufacturers. Hospital pharmacies operate within a Business-to-Healthcare (B2H) model, managing and dispensing medications to inpatients and outpatients, procuring directly from manufacturers or specialized hospital distributors. Public health posts (SUS) primarily receive medicines procured by the government, functioning under a Business-to-Government (B2G) or Government-to-Citizen (G2C) model for dispensing. The retail market is highly competitive, particularly among large chains which hold a significant market share and engage in promotional activities and loyalty programs.

Furthermore, there is a significant B2G relationship between pharmaceutical manufacturers and the Brazilian public health system (SUS). The government is a major purchaser of medicines, especially for essential drugs, high-cost treatments, and vaccines, through public tenders and procurement processes. This relationship is critical for ensuring access to healthcare for the population but also subject to specific regulations, pricing controls, and budget constraints.

Products and Services Exchanged¶

Across the pharmaceutical value chain in Brazil, a diverse range of products and services are exchanged:

Between Input Production and Pharmaceutical Production: The primary products are Active Pharmaceutical Ingredients (IFAs), the core chemical compounds providing therapeutic effect, and excipients, inert substances used as carriers, binders, fillers, or flavorings in drug formulations. Chemical intermediates, precursors to IFAs, are also exchanged in this upstream stage. Services exchanged include quality control testing, technical support related to synthesis processes, and regulatory documentation support for raw material approval.
Between Pharmaceutical Production and Distribution/Retail/Healthcare/SUS: This is where finished pharmaceutical products are exchanged. These include a wide array of dosage forms such as tablets, capsules, injections, syrups, creams, and more. The products are categorized by type:
- Innovative Medicines: New drugs resulting from extensive R&D, often patented.
- Generics: Bioequivalent copies of off-patent innovative medicines.
- Similar Medicines: Drugs with the same active ingredient but potentially different excipients, dosage forms, or manufacturing processes than the reference product, requiring specific testing for efficacy and safety in Brazil.
- Biologics/Biosimilars: Medicines derived from biological sources (e.g., vaccines, insulin, monoclonal antibodies) and their subsequent approved versions.
- Fitoterapics: Medicines derived from plants.
- Manipulated Medicines: Personalized formulations prepared by manipulation pharmacies according to a prescription. Beyond the physical products, services exchanged include regulatory documentation, technical product information, marketing materials, and training for proper handling and storage.
Between Distribution and Retail/Healthcare: Distributors primarily exchange finished pharmaceutical products acquired from manufacturers. Their core services involve logistics, warehousing, inventory management, order fulfillment, and transportation. They ensure products are stored under appropriate conditions (including temperature-controlled transport as per RDC 430/2020) and delivered efficiently to diverse locations across the country. Traceability services, crucial for regulatory compliance and product safety, are also a key part of the distribution offering.
Between Retail and Consumers/Patients: Pharmacies and drugstores exchange medicines (prescription and over-the-counter) and a wide range of non-medicinal products such as personal hygiene items, cosmetics, convenience foods, and wellness products. Increasingly, they also offer pharmaceutical services, including vaccination, basic health checks (e.g., blood pressure, glucose levels), medication counseling, and adherence programs, transforming pharmacies into broader health service providers.
Between Pharmaceutical Production and Government (SUS): The primary exchange is the supply of medicines based on public tenders and procurement contracts. This often involves large volumes of essential, specialized, and high-cost drugs. Services related to supply chain management, delivery logistics to public health facilities, and regulatory compliance for government procurement are also part of this relationship.
Within Pharmaceutical Production (R&D): Exchange includes research data, clinical trial results, intellectual property (patents, licenses), and specialized R&D services provided by CROs or academic institutions.

Business Models¶

The commercial relationships in the Brazilian pharmaceutical value chain are underpinned by various business models:

Manufacturing and Sales (B2B, B2B2B, B2B2C, B2G): This is the core model for pharmaceutical companies. They invest in R&D (for innovative drugs) or focus on production efficiency (for generics/similars) and sell their finished products. Their revenue comes from direct sales to large clients (distributors, hospitals, government) or through indirect sales via distribution channels reaching retail pharmacies and ultimately consumers. Multinational companies often follow a model focused on high-value innovative drugs, while national companies heavily target the high-volume generics and similar markets. Public laboratories operate under a public health mandate, often producing and supplying specific drugs for the SUS.
Wholesale Distribution (B2B): Distributors operate on a volume-based model, purchasing in bulk from manufacturers and selling to numerous smaller customers (pharmacies, hospitals). Their profitability relies on efficient logistics, inventory turnover, and managing margins between purchase and sale prices. They provide a crucial logistical service that manufacturers might find inefficient to replicate nationwide.
Retail Pharmacy (B2C, B2B): Retail pharmacies, especially large chains like RD Saúde, Grupo DPSP, and Grupo Pague Menos, employ a high-volume, high-traffic model. They aim to attract consumers not only for prescription fills but also for a wide range of non-medicinal products and convenient locations. Their business model increasingly incorporates health hubs, offering services like vaccination and basic health checks to increase foot traffic and customer loyalty. Independent pharmacies and associative networks often rely on personalized service and community ties. Manipulation pharmacies have a specialized B2C model focused on custom-compounded prescriptions.
Hospital Pharmacy (B2H): These operate within healthcare institutions, managing medication supply exclusively for patients within the hospital setting. Their model is focused on internal supply chain efficiency, medication safety, and clinical pharmacy services rather than direct consumer sales profit.
Government Procurement (B2G): The government, through the Ministry of Health and state/municipal health secretariats, operates a large-scale procurement model for the SUS. This involves public tenders, price negotiations, and contracts with pharmaceutical manufacturers and distributors to ensure the availability of essential and specialized medicines to the public, often at negotiated lower prices compared to the private market.
Contract Manufacturing (B2B): CMOs offer their manufacturing facilities and expertise to other pharmaceutical companies. Their business model is based on providing production services on a contract basis, allowing companies to outsource manufacturing and potentially reduce capital investment in facilities.
Licensing and Partnerships (B2B): Pharmaceutical companies engage in licensing agreements to gain rights to produce or commercialize drugs discovered by others. Partnerships, especially in R&D, allow companies to share costs and risks associated with drug development.

Bottlenecks and Challenges¶

Despite its significant size and growth, the Brazilian pharmaceutical value chain faces several critical bottlenecks and challenges:

High Dependence on Imported IFAs: Approximately 90% of the raw materials for medicine production are imported. This creates vulnerability to international supply chain disruptions, currency fluctuations, and geopolitical factors. It limits the national industry's autonomy and contributes to higher production costs. There is strong public sentiment favoring increased domestic production.
Complex and Evolving Regulatory Landscape: The pharmaceutical sector is one of the most regulated industries globally, and Brazil is no exception. Navigating ANVISA's requirements for drug registration, manufacturing practices (BPF), distribution rules (RDC 430/2020), and pricing controls is complex and can lead to delays and increased costs. Frequent regulatory updates require continuous adaptation from all players.
High R&D Costs and Risk: Developing new drugs is an extremely expensive and high-risk process. While Brazil's pharmaceutical industry is increasing R&D investment, national companies still lag behind large multinationals in pioneering innovative molecules. This limits Brazil's contribution to global pharmaceutical innovation and keeps the country dependent on importing high-cost patented drugs.
Logistical Challenges: Brazil's continental size and varied infrastructure present significant challenges for the efficient distribution of medicines, especially to remote areas. Ensuring proper storage conditions (like temperature control) across long distances adds complexity and cost to the distribution stage.
Intense Competition in Retail: The retail pharmacy market, while large, is intensely competitive, particularly among the major chains. This can squeeze margins and push smaller independent pharmacies to the brink. The focus on non-medicinal products and services by large chains also alters the competitive landscape.
Pricing Controls and Government Procurement: Price regulation by the government and the nature of public procurement processes for the SUS can impact the profitability of pharmaceutical companies, especially for essential and high-volume drugs supplied to the public sector. Managing these relationships and ensuring sustainable supply to the SUS is a continuous challenge.
Counterfeiting and Illicit Trade: Like many countries, Brazil faces challenges with counterfeit medicines and illicit trade, which pose significant risks to public health and undermine the legitimate value chain.
Need for Skilled Labor and Technology: Maintaining high standards in research, production, distribution, and retail requires a skilled workforce and continuous investment in technology and infrastructure.
Lack of Value Chain Integration: The strong dependence on imported APIs highlights a fragmentation between the input production and pharmaceutical production stages. Strengthening the domestic farmoquímica industry is seen as crucial for increasing national resilience and reducing external dependency. Government initiatives like "Nova Indústria Brasil" aim to address this integration.

References¶

Abradilan. Dez maiores farmacêuticas do Brasil detêm 48,6% das vendas. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAK4dBmW7IL9RJrghI81NrTydx17jDcvLPcJ4rnNRn2f5n8GkMkcFku27e0pt7zAEFjLiJqaY4vDTnyw0BSDp4BDXTX-8HtzLrfoLRx6vssa4XhvxFLdf1kLe4rqa3Hry-GwhRsD4GId0WAZJ2LjBMwewmueCX0nlRG2UtSnxK0xQDM38Z_dcEoRtcqly7wpDf2bEEQq
Abradilan. Dez maiores farmacêuticas detêm 48,6% das vendas. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqALpXuNxLNuYpAUq48iyrcyWHkTee43sqtPbo5sKgazL_0uOyljDTRCA20arcXfsQkJYHlIuPwNOJg3jZVTbD-R3p4AVQuAUnr6LPsZOzTb_BMvq_xKG8mpXhhyTJdAMl1xnbkCfpigFP4VOzx4pu0KpSCRF92zXOLs4jHN9PKMaoOiEo-0RLXfJUkHIQc-DnT-xyvA=
Abradilan. Crescimento das grandes redes de farmácias. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAJQvM2Bbhx0gRiEaCgbjryC4a51OVqPyYh9AEXJmJnBtkvcO9voUj4vOBer-GpuM9d52e3lxpapdndt6uF-Yz_k2QJ7iN7ukVsS6SMJ4bCMOVLArW2Y28op7s2tRE0MG3yt0o65C0PWDBhNmKI7QorBJJkxUeQqIlkLrOkQTvtkZbNhAYQPHw==
Abradilan. Setor farmacêutico cresce 12,7% em 2024, mas reajuste autorizado gera dúvidas e impacto no bolso do consumidor. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAJ6oewzup0MipyduN_YHEGepVM7-62jACI8s2nBbIJ-3AJFMY1UNg9FFM-JBqiqymPaEx0GL0OYBsiSZ-Zvx0qQjNvrNEmPz6m4KI_YAzdvSIntrzqIr-xzlffWuKki22R_tebGxIYeTb97cOMG0IJQda_-wHafXM9xTPi-y8zpGCHXj2rJiIkV47b6J-1Ht50f1swI9KjvTqrm1mZwbHkyyZXp12cW4cNQDPAHL-0Th63snYfvWUVxIZ2DLayII8-E7XkktdOfsw==
Agência Gov. Nova Indústria Brasil contribuirá para fortalecer produção de medicamentos. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAK5Kv9aeoW7mQcz7FY1jkZ1INxL5cQgkt7AIc3-i4Ch4QDZqHqf2-sAy7fa5QYJkZHGB1YgUkuEFvMMt-B0El11vD9EwIfMrWeBZOeUZfjBC2VNU2BCVTA5cw8Dx8mlkRgoXbokOIlm1UAxOzkukZ2caTo-szPj2NOdJ16IzjQOruC0gmFuzq5VXWcuI8RhR1jXY3ML93Qn-8GLKcYV5uCIez_XaKylfOvUvTG7Fjo=
CNN Brasil. Brasil importa 90% da matéria-prima para a produção de medicamentos. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAJkEXBgRqERKM3OU_1a5P2V1bZL2YlQQkpi0NR3QpPWDTKCsWS6XYRohS5UlGSS-ROeAtK3rZKJA9rJbqXzq2cpVP1--_5IF4C7P9BfRm7pS1vh08F9uTrRyNkl36LxoLR4IoRPdvMN1eDexnFCcOAcJ4XsCEud98QONXeXR7cTH38qvWKn_ybIceqVFaztln4f2JV8W4RkH1IgJz4=
Febrafar. Varejo farmacêutico: veja destaques de 2024 e expectativas para 2025. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAKM2-l05VCBsp7WQvPVjFuC3u6Jc0hcd0aTLW5mQVfaSl75mWVgEIxcZPq80Dv4ohIsFtH167y1h6qCcwp_IR44Q3w2cQfdMZLxP1rMMV-yMQUWmSW3fZRvrRR3uLLcIMJKgjCWvaPuiScFDNv4F1wr2K1ZkUHEXHiA1msHYAxkMXnmg16SmUOWirPA4ca2tVvEMA==
FIA. Indústria farmacêutica: características, setores e mercado de trabalho. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAKookK2CQWz2tEgTJ0j_F0pBsgoqtjkZX0ZeT5gsx-S0cNeEaXOzPrQ8CzvOORCTk59VD1Y2swU0eB35_1VxIkKGY5GWTN7yj_WuzWS7r2pmlNIlXvllByL0eEhzwBNV8JQgCCOog==
ICTQ. 14 atualizações regulatórias para a Indústria Farmacêutica em 2018. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAKu-mC6S157t6K7EBEnAiOLaLWmM7MontA5Td_VmJnnaOBj5ddWHZNxAxNncFhCcWfwwnkeOjVwmrMtKBwWYokC7yUGoDplUf8cGH5lXeWIHQJraSRbSZksTaGagcFWXOFyIY619tF902odELU0_olAjJfqGkF21xuoJNulK0OiExw8hsHNgrEmBqghNDvjMe1DQa4S05RCcM3COzqtLF1sQ_bMurUbAQ==
ICTQ. Os modelos de negócios farmacêuticos. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAIDIs1EXmr0VX2UaHFTyFmlDgRMdb39NLBfcqSiBZgfflx7WaYivX5C0haEQxlpCAPgoymRl-mQ5ir_A5uk9wuB49rKMOXJADTn3ylJIUADw17Yrat__aoZrwv7ZNkCHbkwKKh9zYe_YthUi4B1YgbITFRr6sCoOqTBKe-iSPdejd9DwzQe
InvesteSP. Setor farmacêutico é o que mais investe em pesquisa e desenvolvimento. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAKI7DFTS-I3JlUk2dRk4u3WTrV3k-2_qAG6X_cwCznMOB8zdDAtEg0jCLy-sTtqbldWP1SzkycYrCyWK6J8f-ERZZWfjC2sy6r4OLRNCo8rJB7geBaiji78G4K9tp9yPlHV1kCkhMSUbfh3ycnGiDdN4UHIO7iSu_xiK_mhnLAvRd0xDLVo4gFDM26iD5IsLhtor560Knlju7S1usuQwdq57Ao=
ICTQ. Anvisa - Confira as principais atualizações regulatórias que ocorreram nos últimos seis meses. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqALPVMuXn_y5xwz3c2_zaD4ZbEZQGF5x6WRcZ3wZ49Nq5JVlaw_MskHDuOx8DJWW_qzM9WxZaReHgdEEa2jawEf4lOG0LaVWOJMNzZ_AcMRwgwE5Q_P4K2dHnAZAqxZnf1FpF5cKMhuoRZclr_JTES8kpqKRGnPN_AtLreKWnuh2JtbfYGkkafG6kxuyUx13GbZ1CkbyNfecMRTETLI4zT9N9PDRXq-zZboNbHSsnAVOgLBRB8QzHPpbR5uI8zUl787_
Medicina SA. 90% dos brasileiros preferem a produção de medicamentos e insumos no país. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqALRfFyn4myA06BTLPLsw4ZjKhLysuixsN-x1uPBY_jpKFarhXPXVJ-iX6JaDKpq-MZkkqQaA5YzvAIovU8p1wkKq1bItWutaZl7bXbQCu9tvDkCkkCeWdUv0hZDIQiLA3dyPInTBWg=
Medicina SA. Três grandes grupos de redes de farmácias concentram 40% do mercado no Brasil. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqALt0gL0jgjYp84ICSxVmPrid3Wljdfvx8RZrFI_fb8dZMYIKdXH7lkeRJQVVr03mtdGz_WnJpH0RI6Wke_6kxcSUsyIYBsHKG7nE1Z7Jq6OSlIUKn42uSGgd2bE59Gdl8-w1YAgc_KJdBS41WXI5uOYkDUWCEIbAfhD_lgUz2lfakMFunYptYP4hul_fW7zkMhB1JM2fTR6h44xZkMtJv6c6ZyDp3Jn
Medicina SA. Três grandes grupos de redes de farmácias concentram 40% do mercado no Brasil. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAIk34XBoqasSLvxVKCo9esjEaCOKMUG-xT1BYilO8bi3GrTiQUpYtshRQCKMo53MjQbGvLPD50Q2OAp8QI-CUQpkclD8dGGnTdYG9JdOKStsVMMUiW2tl1rPWdIFGw1M24=
Medicina SA. Varejo farmacêutico cresce 11% e movimenta R$ 158,4 bilhões em 2024. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAI08jkENfgmtq0pdfAglEEqmva87EFi02Nnl6XzbaLvJuSf0sVr06tzIn-3e-fNYZgWmSNQEzdNQaCB6NXpQD-JdLYHBjRVWsurGaxskgHmRoGMefB2-vT9bzuUwcAwYdPCgL0Q
MOOC Fiocruz. Indústria Farmacêutica no Brasil: um breve panorama. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAKfeo_M1IRzxZdKgzm61fIQTNHqHxNKQNCjFPmoxYlzxKnSUj_79D0-tAke-J5vrhSFno-gPNlPw5PnM-OegK1wzDYGs7wtQJTQRF9KlbsCbMrDo0kPMzxdzVEtFkGwC4z39A3sHfMc2_eNWJxxJVRDo-CLQtSWOKcxQjNq3vaqNrRG55vCfz6TVC_du-1WzmM3C1XwdqcME9334I_kXb486WeRO895FYK5Rk4=
Omni Hospitalar. Como funciona o processo de distribuição de medicamentos?. https://vertexaisearch.google.com/grounding-api-redirect/AWQVqAIVmYqqNGSA0N8hZdyJkWIGCnBPAqD8Vlg9_03oIRZNfhX1GD96pQq2B0S0AnSMF-cpGbHDNNQHRi29_QflBjIy-Iut00FV12RLnC7iNmxtDfDWY-7DrpVc3ukmFHJeVpjrW0SgC-8QzhYEd6THPLifn_crM3LZeybcqddfx_UM5yDVQfP-gfapEIWAUD8UlF_6QTwCUq0C6g==
Medicina SA. Três grandes grupos de redes de farmácias concentram 40% do mercado no Brasil. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAIk34XBoqasSLvxVKCo9esjEaCOKMUG-xT1BYilO8bi3GrTiQUpYtshRQCKMo53MjQbGvLPD50Q2OAp8QI-CUQpkclD8dGGnTdYG9JdOKStsVMMUiW2tl1rPWdIFGw1M24=
VEJA. 90% dos brasileiros dizem que produção nacional de remédios deve aumentar. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAKFX7A5G6MJJTxDYG6-9n530mtZYiAJRnWPXkvhWFuPgQby1S-W35pg4ld5tPb3TfLx7uVazsnt6Ck0o5FJc4Ac3usRHUR0K4cWbEIUhyjA9igkRwW34jZDTFm_Ok5hsZc0uryiyawYQXKOX4ntXME0_mu82GHx-MmKZiqQ-Rp0XcsdaPI-xEcd3zSqBrp48NIBzKhkAef4aW3JuxcnWg==
VEJA. Varejo farmacêutico cresce 11% e movimenta R$ 158,4 bi em 2024. https://vertexaisearch.cloud.google.com/grounding-api-redirect/AWQVqAK9_96l4BPgvD9CwbNugxCIuz1QVJhf67tbK4Nwzk02qecdzNfxJvkJo8yxxMbYLKvgyfmNoIf16ThHVqruJCcOCFWIPUkf3Kz0fL9_iUm0u-lMa4VfDF4oNezCjEnM79vHNSLnjZjtPJPvbFYYw-jQ517bVz5MlgY96MXeHG9QV8psa-vIDG1Wc-LjuZwHIy74Z-fbBSQ1OHQi